{"nctId":"NCT01223703","briefTitle":"PUFAs and Left Ventricular Function in Heart Failure","startDateStruct":{"date":"2007-11"},"conditions":["Dilated Cardiomyopathy","Heart Failure"],"count":133,"armGroups":[{"label":"n-3 PUFAs","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: n-3 PUFAs"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"n-3 PUFAs","otherNames":["OMACOR, Pronova Biopharma, Lysaker, Norway"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients with a diagnosis of non ischemic cardiomyopathy (the absence of coronary artery disease,defined as the absence of stenosis \\> 50%, was confirmed by angiography performed at the time of the diagnostic workup of the cardiomyopathy)\n* LV systolic dysfunction (defined as an EF \\< 45%)\n* Stable clinical conditions with minimal or no symptoms for at least three month\n* Evidence-based medical treatment at maximum tolerated target doses for at least six month\n\nExclusion Criteria:\n\n* presence of symptoms or evidence of CAD diagnosed through noninvasive tests;\n* peripheral arterial disease;\n* presence of congenital or primary valvular heart disease;\n* persistent atrial fibrillation;\n* inability to perform bicycle ergometry for noncardiac causes;\n* moderately to severely reduced functional capacity;\n* NYHA functional class IV;\n* poor acoustic windows limiting the ability to assess echocardiographic measurements;\n* chronic lung disease;\n* advanced renal disease (eGFR \\< 30 mL/min/1.73 m2);\n* advanced liver disease;\n* any disease limiting life expectancy to one year or less;\n* contraindications to study drugs;\n* concomitant participation in other research studies","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up","description":"The primary end point of the study was the change in LV systolic function expressed as LVEF between baseline and 12-month follow-up. The following parameters were measured according to the professional standards defined by the American Society of Echocardiography and the European Association of Echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":"7"},{"groupId":"OG001","value":"37","spread":"6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":"6"},{"groupId":"OG001","value":"35","spread":"6"}]}]}]},{"type":"SECONDARY","title":"LV Diastolic Function","description":"Change in LV diastolic function assessed by echocardiography: mitral diastolic inflow velocities (peak velocity of early ventricular filling \\[E-wave\\], peak velocity of late ventricular filling \\[A-wave\\], E/A ratio, and E-wave deceleration time), diastolic function score (graded on a scale from 1 to 4) were used.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.29"},{"groupId":"OG001","value":"0.90","spread":"0.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.19"},{"groupId":"OG001","value":"0.98","spread":"0.40"}]}]}]},{"type":"SECONDARY","title":"Functional Capacity (Change in Peak Oxygen Uptake, VO2)","description":"Change in functional capacity expressed as a peak oxygen uptake (VO2), that was acquired breath-by-breath by pneumotachograph (with bidirectional differential pressure) during cardiopulmonary exercize testing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":"3.8"},{"groupId":"OG001","value":"18.3","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":"4.3"},{"groupId":"OG001","value":"17.4","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Change in Mean New York Heart Association (NYHA) Functional Class Between Baseline and 12th Month Follow up.","description":"NYHA class I: No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs, etc...\n\nNYHA class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.\n\nNYHA class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest NYHA class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"0.51"},{"groupId":"OG001","value":"2.17","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"0.54"},{"groupId":"OG001","value":"2.32","spread":"0.61"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}